Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients With Alzheimer Disease

Geum Sook Shim, MD Do-Hyung Kang, MD Jun Soo Kwon, MD, PhD Department of Psychiatry Seoul National University College of Medicine Seoul, Korea

Patients were eligible for this double-blind, placebo-controlled, randomized, 6-month trial if they were 50 years old or older, ethnic Chinese in Hong Kong, had progressive decline in memory and cognitive function for 6 months, had National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer Disease and Related Disorders Association diagnosis of probable or possible AD,13 and gave written informed consent. For subjects unable to understand the study and their role in it, consent was obtained from the caregivers. Exclusion criteria were anticoagulant or antiplatelet treatment or bleeding risk factors, current smoking, or severe illness making study completion unlikely. The study was
Butylated hydroxytoluene was added to spectrometry-mass spectrometry prestudy Cantonese MMSE once daily, with stratification by their acid, and vanillin were measured in curcumin, bisdemethoxycurcumin, tetra-
treated and monitored for 1 month. Patients were recruited but could only be treated and monitored for 1 month. Patients were randomized to 4, 1 (plus 3 g color-matched placebo powder), or 0 g of curcumin (plus 4 g of placebo) once daily, with stratification by their prestudy Cantonese MMSE score range (<14, 14–17, or >17) to improve matching of baseline scores among dose groups. Of 22 patients randomized to 4 or 1 g, 10 patients chose to take curcumin/placebo as 10 capsules to swallow after a meal; and 12 patients, as a packet of powder to mix with food. Patients were permitted to continue (or to change at any time) any treatment deemed appropriate by their physicians and were also given as a standard treat-
ment, which showed moderate benefit in previous studies, 1 capsule/d 120 mg standardized ginkgo leaf extract (Shanghai Charoma, Shanghai, China). Curcumin was given by Kancor Flavours, Kerala, India, for packets, or bought from Arjuna Natural Extracts, Kerala, India, for capsules.

At 0, 1, and 6 months, plasma was taken to measure isoprostanes iPF2α-III and antioxidants, and so was serum to monitor Aβ and liver and kidney function. At 1 month, plasma was taken to assay curcumin and metabolites. Mini-
State Examination was administered at baseline and 6 months. Amyloid β was measured by enzyme-linked immunosorbent assay (Covance, Dedham, Mass). Curcumin is a mixture of 3 similar molecules—curcumin, demethoxycurcumin, and bisdemethoxy-
curcumin (CDB), the former being most abundant. Curcumin, demethoxy-
curcumin, bisdemethoxycurcumin, tetrahydrocurcumin, ferulic acid, vanillic acid, and vanillin were measured in plasma by liquid chromatography–mass spectrometry-mass spectrometry after β-glucuronidase treatment (Sigma, St Louis, Mo). To measure isoprostanes, blood was collected in lithium-heparin tubes with 15 μM of indomethacin. Butylated hydroxytoluene was added to plasma to 20 μM. Isoprostanes were enriched by an affinity column and measured by gas chromatography–mass spectrometry. High-performance liquid chromatography assays measured antioxidants: plasma glutathione peroxidase and superoxide dismutase activity, ascorbic acid, uric acid, and vitamins A and E. Continuous variables were compared by testing for normality (Kolmogorov-Smirnov test) and then analysis of variance or t test for normal distributions and Wilcoxon or Mann-Whitney U test otherwise. Discrete variables were compared using χ² test.

Thirty-four subjects began the 6-month trial. Of 27 finishing it with less than 30 cumulative days off the study drug (8 subjects on 0 g, 8 on 1 g, and 11 on 4 g), baseline clinical measures were matched across dose groups: ages (mean ± SD) were 77.8 ± 7.7 years on 0 g, 69.0 ± 10.9 on 1 g, and 73.4 ± 6.6 on 4 g (P = 0.14); male subjects were 3 of 8 on 0 g, 1 of 8 on 1 g, and 3 of 11 on 4 g (P = 0.52); and MMSE scores (mean ± SD) were 15.4 ± 5.8 on 0 g, 15.4 ± 5.0 on 1 g, and 15.6 ± 7.9 on 4 g (P = 1.0). Of the other 7 subjects, 0 were on 4 g/d curcumin, 3 on 1 g, and 4 on 0 g (P = 0.11); 3 withdrew for gastrointestinal complaints, 3 for falls or dizziness, and 1 for respiratory tract in-
fec tion. To monitor safety, sodium, potassium, urea, creatinine, protein, albumin, bilirubin, alkaline phosphatase, and alanine aminotransferase/glutamic-pyruvic transaminase were measured, but any toxicity not affecting these values might have been missed. Changes in none of the values between baseline and 6 months differed significantly among dose groups. Adverse events totaled 7 on 0 g, 6 on 1 g, and 2 on 4 g: 4 gastrointestinal (2 on 0 g, 2 on 1 g, and 1 on 4 g), 3 respiratory tract infections (2 on 0 g and 1 on 1 g), 3 falls or dizziness (1 on 0 g, 1 on 1 g, and 1 on 4 g), 2 delusional (1 on 0 g and 1 on 4 g), 2 edema (1 on 0 g and 1 on 1 g), and 1 hearing impairment (0 on 0 g). Power was 14% to detect an α of 0.05 difference between curcumin and 0 g in MMSE changes of the same effect size as a 24-week donepezil study.

Changes in MMSE scores between 0 and 6 months were compared among dose groups, either including (mean ± SE, 1.3 ± 0.6 on 0 g; −0.6 ± 1.0 on 1 g; and 0.7 ± 1.1 on 4 g; P = 0.43) or excluding (P = 0.37) patients on vitamin E or standard AD drugs, and between 0 g and curcumin (mean ± SE, 1.3 ± 0.6 on 0 g; 0.2 ± 0.7 on curcumin; P = 0.39) for patients using capsules (mean ± SE, 1.5 ± 0.7 on 0 g, −0.2 ± 1.3 on curcumin; P = 0.34) or packets (mean ± SE, 0.0 ± undefined on 0 g; 0.5 ± 0.8 on curcumin; P = 0.86). Serum Aβ40 levels (Fig. 1) did not differ among doses at 0 (P = 0.63), 1 (P = 0.78), or 6 months (P = 0.36). Between baseline and 6 months, serum Aβ40 (mean ± SE) changed from 30 ± 6 ng/L to 26 ± 3 on 0 g and from 28 ± 6 to 35 ± 7 on 4 g (P = 0.15). The change in serum Aβ40 between baseline and 1 month did not differ between patients taking curcumin as capsules (mean ± SE, 26 ± 18%) or powder (mean ± SE, 27 ± 22%; P = 0.66). The change in plasma isopros-
tanes (mean ± SE) between baseline and 6 months did not differ among doses (P = 0.23): −11 ± 10 for 0 g, 12 ± 10 for 1 g, and 6 ± 8% for 4 g. The change in isoprostanes between baseline and 6 months did not differ between patients taking curcumin as capsules (mean ± SE, 15 ± 7%) or powder (mean ± SE, 4 ± 9%; P = 0.43). Over 1 month, vitamin E levels changed, 1 ± 3% with curcumin (8 ± 2% for capsules vs −4 ± 5% for powder; P = 0.05) versus −21 ± 5% with 0 g (P = 0.001), and the percent change of vitamin E levels correlated positively with the total curcuminoid level (P = 0.01; Pearson correlation); patients taking vitamin E supplements were excluded.

In a preliminary experiment, curcumin was measured in plasma from 1 nondemented control subject at various times after 4 g of curcumin either with or without food. No signal was detected unless the plasma was first treated with glucuronidase, demonstrating that nearly all the curcumin was glucuronidated. The level of curcumin (CDB) peaked at 250 nM at 1.5 hours with food and at 270 nM at 4 hours with only water. At 24 hours, the level fell to 60 nM. Based on these findings, we decided to measure curcumin 2 to 2.5 hours after ingestion. There were no significant differences in levels of any curcumi-
noids or of total curcuminoids between 1- and 4-g groups; thus, both groups
were pooled for calculating mean ± SE (in nanomolar) levels: 250 ± 80 curcumin, 150 ± 50 demethoxycurcumin, 90 ± 30 bisdemethoxycurcumin, 440 ± 100 tetrahydrocurcumin, 110 ± 20 ferulic acid, 50 ± 20 vanillic acid, 490 ± 160 CDB, and 1100 ± 260 total curcuminoids. No vanillin was detected in any samples. One patient receiving 1 g/d had total curcuminoid levels 2.8 times as high as any other patient, and when this patient was excluded, total curcuminoid levels tended to be greater with 4 g than with 1 g (P = 0.15): 1040 ± 150 versus 650 ± 210. Patients taking capsules (taken fasting with water; 10 patients) had greater levels of CDB than did patients taking powder (with a little food; 12 patients): 940 ± 290 versus 120 ± 40; P = 0.02. However, levels of tetrahydrocurcumin, ferulic acid, or vanillic acid did not differ between patients on capsules or powder.

**DISCUSSION**

As the first study published on curcumin treatment of AD patients, this trial provided data on side effects, drug absorption, and biological effects. Curcumin may act in AD by several possible mechanisms, including Aβ disaggregation, anti-inflammation, and antioxidation.2,3,7,8,19 The lack of cognitive decline on placebo in this 6-month trial may have precluded any ability to detect a relative protective effect of curcumin, which presumably would have appeared as a slower decline rather than an improvement in cognition. A study of longer duration, with a more sensitive test such as the Alzheimer Disease Assessment Scale–cognitive subscale and perhaps less treatment by other AD drugs, may show greater deterioration on placebo.

The greater level of curcumin but not tetrahydrocurcumin, ferulic acid, or vanillic acid after capsules than powder may be due to more absorption and less metabolism of curcumin from capsules, suggesting that capsules be used in future trials. The lack of difference in curcumin or metabolite levels between 1- and 4-g groups suggests that there may be no need to exceed 1 g in future trials. Curcumin prevents or reverses half of the aggregation (IC_{50}) of Aβ at 0.2 to 1 μM CDB.7,8 In this study, mean plasma CDB was 490 nM (940 nM for capsules). A study in mice found that curcumin reached similar concentrations in the brain as in plasma: 0.41 μg/g in brain and 0.60 μg/g in plasma.12 Thus, curcumin may reach brain concentrations sufficient to decrease Aβ aggregation. Metabolites of curcumin might contribute further; the IC_{50} of ferulic acid is 2 to 10 μM, and tetrahydrocurcumin has not yet been tested.20

Plasma antioxidants, including glutathione peroxidase and superoxide dismutase activity; uric acid; and vitamins A, C, and E, were reportedly decreased in AD.11 We found that curcumin raised vitamin E. One interpretation is that the antioxidant activity of curcuminoids might decrease need for and depletion of the antioxidant vitamin E. Another possibility is that curcumin slows AD progression, reducing oxidation because of processes within the AD brain.

Although serum Aβ_{40} levels did not differ significantly among doses, serum Aβ_{42} tended to rise on curcumin, possibly reflecting an ability of curcumin to disaggregate Aβ deposits in the brain, releasing the Aβ for circulation and disposal.7,8 Curcumin did not seem to cause side effects in AD patients (rather, there was a tendency toward fewer adverse events on 4 g). Thus, longer and larger trials to test the efficacy of curcumin for treating AD may be safely commenced.

**ACKNOWLEDGMENTS**

The authors thank the patients and their families who participated in this study. The authors also thank Kancer Flavours, for donating curcumin, and Aynun Begum, Aniko Solyom, and Manfred Metzl, for giving curcuminoid samples.

This study was supported by a Chinese University of Hong Kong direct grant, a Chinese University of Hong Kong Institute of Chinese Medicine grant, and a BUPA Foundation grant.

Larry Baum, PhD*
Christopher Wai Kei Lam, PhD*
Stanley Kwok-Kuen Cheung, MSc*
Timothy Kwok, MD*
Victor Lui, MRCPSYCH
Joshua Tsok, MRCPSYCH
Linda Lam, MD, MRCPSYCH
Vivian Leung, FHKCPsy
Elsie Hui, FRCP
Chelsia Ng, HBSc
Jean Woo, MD*
Helen Fung Kum Chiu, FRCPsy
William B. Goggins, ScD*
Benny Chung-Ying Zee, PhD*
King Fai Cheng, MD*
Carmen Yuet Shim Fong, RN*
Adrian Wong, BSc*
Hazel Mok, BSc*
Moses Sing Sum Chow, PharmD#
Ping Chuen Ho, PhD#
Siu Po Ip, PhD**
Chung Shun Ho, PhD#
Xiong Wen Yu, PhD#
Caroline Yau Lin Lai, MMEDSc
Ming-Houng Chan, FHKCPsy
Samuel Szeto, FRCP*
Iris Hiu Shuen Chan, PhD*
Vincent Mok, MD*

*2008 Lippincott Williams & Wilkins

FIGURE 1. Mean ± SE plasma Aβ_{40} levels in dose groups among subjects completing the 6-month study: placebo (open circles), 1 g/d curcumin (small closed circles), and 4 g/d curcumin (large closed circles).
Departments of *Medicine and Therapeutics  
†Chemical Pathology  
‡Psychiatry  
‖School of Public Health  
§Centre for Clinical Trials  
‖‖Clinical Trials Section  
Institute of Chinese Medicine  
#Drug Development Centre  
**School of Chinese Medicine  
The Chinese University of Hong Kong  
Shatin  
Kwong Wah Hospital  
Kowloon, Hong Kong  
China  
lbaum@cuhk.edu.hk

REFERENCES